Grant: Discovery Grants Program - Individual
University of Alberta
$120,000.00
Multivalence assisted supramolecular assembly in biological systems and glycoconjugate vaccines
EF 2012-13
Résumé
Our interdisciplinary research program focuses on the chemical biology of complex oligosaccharides with particular emphasis on two specific areas; conjugate vaccines and molecular recognition events that employ multivalency and supramolecular effects. The NSERC discovery grant is used to support research for the discovery and development of robust chemical methods to create and chemically define novel, biological active, compounds with potential for drug development.
The target conjugate vaccine antigens are microbial cell wall oligosaccharides and mammalian tumour associated glycolipids, especially gangliosides, lipid antigens that are known to afford protection against cancer when administered as vaccines. We are developing novel chemistry for highly efficient covalent bond formation between carbohydrate antigenic determinants and immunogenic proteins, while ensuring the antibody response is focused on carbohydrate rather than the tether that links the two parts of the vaccine. We employ simple synthetic substrates that closely resemblenatural lipid and apply in vitro or in vivo chemoenzymic synthesis to complete the biosynthetic transformation of our substrate into vaccine precursors.
We have developed novel concepts in the design of inhibitors to block toxin binding to cell surface oligosaccharide receptors and we are expanding this concept to include other cell surface receptors. The approach employs pre-organized heterobivalent ligands in a defined polymeric array. Their exceptionally high activity depends on their ability to bring together two proteins that bind weakly to one half of the ligand but strongly when both ends of our molecule are engaged by each protein. The increase in binding strength can approach a million to one billion. Practical applications include protection from otherwise fatal doses of bacterial toxin such as E. coli O157 and targeting of malignant cells. This design concept has numerous potential applications that are not limited to carbohydrate head groups. We are cognizant of these possibilities and will not limit our investigation to purely carbohydrate recognition elements.
Programme
Discovery Grants Program - Individual
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
138355-2008
Name nom
Bundle, David
Department département
Chemistry
Organization id
9
Institution établissement
University of Alberta
Province en
Alberta
Province fr
Alberta
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2012
Competition year année de concours
2008
Award amount
120000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
24
Committee name en
Inorganic & Organic Chemistry
Committee name fr
Chimie inorg. et org.
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
3702
Research subject group en
Organic chemistry
Research subject group fr
Chimie organique
Research subject en
Carbohydrates
Research subject fr
Glucides
Partie
5
Nb partie
5
Application title
Multivalence assisted supramolecular assembly in biological systems and glycoconjugate vaccines
Keyword
NSERC
Application summary
Our interdisciplinary research program focuses on the chemical biology of complex oligosaccharides with particular emphasis on two specific areas; conjugate vaccines and molecular recognition events that employ multivalency and supramolecular effects. The NSERC discovery grant is used to support research for the discovery and development of robust chemical methods to create and chemically define novel, biological active, compounds with potential for drug development.
The target conjugate vaccine antigens are microbial cell wall oligosaccharides and mammalian tumour associated glycolipids, especially gangliosides, lipid antigens that are known to afford protection against cancer when administered as vaccines. We are developing novel chemistry for highly efficient covalent bond formation between carbohydrate antigenic determinants and immunogenic proteins, while ensuring the antibody response is focused on carbohydrate rather than the tether that links the two parts of the vaccine. We employ simple synthetic substrates that closely resemblenatural lipid and apply in vitro or in vivo chemoenzymic synthesis to complete the biosynthetic transformation of our substrate into vaccine precursors.
We have developed novel concepts in the design of inhibitors to block toxin binding to cell surface oligosaccharide receptors and we are expanding this concept to include other cell surface receptors. The approach employs pre-organized heterobivalent ligands in a defined polymeric array. Their exceptionally high activity depends on their ability to bring together two proteins that bind weakly to one half of the ligand but strongly when both ends of our molecule are engaged by each protein. The increase in binding strength can approach a million to one billion. Practical applications include protection from otherwise fatal doses of bacterial toxin such as E. coli O157 and targeting of malignant cells. This design concept has numerous potential applications that are not limited to carbohydrate head groups. We are cognizant of these possibilities and will not limit our investigation to purely carbohydrate recognition elements.